Cardiac Rhythm Management

35 Years of Innovation.  Exploration.  And Making More Possible.

For over 35 years, Boston Scientific Cardiac Rhythm Management has helped to make more possible for physicians around the world. From introducing the first commercially available ICD to sponsoring nearly two decades of ground-breaking clinical research, Boston Scientific has built a legacy of innovation, clinical science, and collaboration. But our commitment to electrophysiology is not all behind us. We’re continuing to build on our tradition with smaller devices, rigorously designed clinical trials, and world-class medical education and physician training programs. All to help you make more possible for your patients.  

Important Safety Information
ICD Systems from Boston Scientific CRM »
CRT-D Systems from Boston Scientific CRM »

Innovation		Clinical Science		Collaboration
Nearly 30 years ago, our researchers partnered with a visionary physician to introduce the first commercially available ICD. Since then, we’ve delivered a host of other breakthrough technologies – including the first transvenous defibrillation lead and the first U.S.-approved CRT-D. And, our commitment to innovation continues. Today, we’re investing in the next generation of technologies to help you save and improve patients' lives.		We’ve been there from the start, working tirelessly alongside you to help define the practice of electrophysiology. In fact, more than 80% of U.S. patients who receive an ICD or CRT-D were first indicated for this lifesaving therapy by a landmark trial sponsored by Boston Scientific.** Today we’re building on this legacy by investing in new clinical research – rigorously designed studies with clinically relevant endpoints that could redefine the possibilities for you – and your patients.		Throughout our history we have maintained a strong commitment to medical education. And to providing physicians and allied health professionals with world-class programs to help advance the standard of patient care. Today, this spirit of collaboration is embodied in our hands-on product training, electrophysiology fellows development programs and comprehensive continuing education offerings.
[+] View Details Invested an estimated $1.1 billion in company-wide R&D in 2007* Put the highest percentage of sales into R&D among publicly-traded manufacturers of CRM devices* Continuing company-wide dedication to advance CRM by investing in the next generation of devices through internal R&D and equity investments Introduced the COGNIS® CRT-D and TELIGEN® ICD, the world’s smallest, thinnest high-energy devices, demonstrating our meaningful innovation Developed a comprehensive portfolio of LV leads, including four fixation designs – the most options on the market Ongoing commitment to quality, reliability, and continuous process improvement		[+] View Details History of breakthrough clinical science with landmark trials like MADIT, MADIT II, and COMPANION that expanded therapy indications to more patients Pioneering research to give physicians clinically relevant and actionable data to help enhance therapies for patients with life-threatening heart conditions Continuing our legacy by sponsoring MADIT-CRT, an important continuation of nearly two decades of MADIT trials Sponsoring studies that seek to understand tailored therapy options that can optimize patient outcomes such as INTRINSIC-RV, PEGASUS CRT, SMART-AV, and APPROPRIATE Demonstrating continued commitment to meaningful clinical science with plans to enroll thousands of patients in clinical studies in 2009		[+] View Details Institute for Therapy Advancement – a reflection of our commitment to training that helps physicians worldwide stay current with clinical developments Electrophysiology fellows development programs support education on the latest cardiovascular therapies with an emphasis on awareness and adoption Sponsorship of educational programs and symposiums at industry meetings such as HRS, HFSA, and AAHFN Programs like Connect4 that connect R&D engineering and physicians for one-on-one training and direct feedback to advance technology Close the Gap – an educational program aimed at addressing disparities in cardiovascular care for women, black Americans and Latino Americans

*Based on 2007 quarterly analyst reports and information analysis of public earnings by major CRM manufacturers. Data on file.

** ICD and CRT-D implant estimates using full-year 2007 data as of 8/08/08, including Boston Scientific CRM implant data, third-party implant data, and publically available industry information including analyst calls and earnings releases. Data on file at Boston Scientific. All calculations include indicated, on-label uses only.
Primary prevention: First indication calculation for MADIT II (2002) assumes ischemic primary prevention patients with EF < 30%. Available data suggest 58% of primary prevention patients are ischemic and 71% of those patients have an EF < 30%. Of the primary prevention implants, 42% were first indicated by MADIT II.
Secondary prevention: Of these total implants, 100% were first indicated by either MADIT (1996) or the trial that led to approval of the first defibrillator (1985) Mirowski M, Mower MM, Veltri EP, Juanteguy JM, Reid PR:  Recent clinical experience with the automatic implantable cardioverter defibrillator. Cardiol Clin 1985;3(4):623-30.
Heart failure: Of these CRT-D implants, 100% were first indicated by either COMPANION (2004) or CONTAK CD (2002).